Increased rosuvastatin dose versus concomitant fenofibrate and rosuvastatin therapy to achieve lipid goal in patients with diabetes or atherosclerosis with metabolic syndrome

Acta Cardiologica Sinica

Volumn 29, Issue 5, 2013, Pages 421-428

  Chen, Yeh Peng ^a   Chang, Kuan Cheng ^a   Tseng, Wei Kung ^b   Yin, Wei Hsian ^c   Chen, Jaw Wen ^d   Lee, Yuan Teh ^a,e   Wu, Chau Chung ^e  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b E DA HOSPITAL   (Taiwan)

^c CHENG HSIN GENERAL HOSPITAL   (Taiwan)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Combination therapy; Diabetes; Fenofibrate; Metabolic syndrome; Monotherapy; Statin

Indexed keywords

AMINOTRANSFERASE; CHOLESTEROL; CREATININE; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOTRANSFERASE; ROSUVASTATIN; TRIACYLGLYCEROL;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIABETES MELLITUS; DRUG DOSE INCREASE; FEMALE; HUMAN; KIDNEY FUNCTION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MONOTHERAPY; THERAPY EFFECT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84886923743     PISSN: 10116842     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Tseng CS. Mortality and causes of death in a national sample of diabetic patients in Taiwan. Diabetes Care 2004;27:1605-9.
2. Reiner Z, Sonicki Z, Tedeschi-Reiner E. Physicians' perception, knowledge and awareness of cardiovascular risk factors and adherence to prevention guidelines: the PERCRO-DOC survey. Atherosclerosis 2010;13:598-603.
3. Gotto AM Jr. Review of primary and secondary prevention trials with lovastatin, pravastatin, and simvastatin. Am J Cardiol 2005; 96:34-8.
4. Expert panel on detection, evaluation and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult treatment panel III). JAMA 2001;285:2486-97.
5. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet 2004; 364:685-96.
6. Barter PJ, Rye KA. Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome? Arterioscler Thromb Vasc Biol 2008;28:39-46.
7. Grover SA, Coupal L, Zowall H, et al. Evaluating the benefits of treating dyslipidemia: the importance of diabetes as a risk factor. Am JMed 2003;115:122-8.
8. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34.
9. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-61.
10. Scott R, O'Brien R, Fulcher G, et al. Effect of fenofibrte treatment on cardiovascular disease risk in 9795 individuals with type2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 2009;32:493-8.
11. Goff DC Jr, Gerstein HC, Ginsberg HN, et al. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007;99:4i-20i.
12. The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl JMed 2010;362:1563-74.
13. Wu CC, Sy R, Tanphaichitr V, et al. A multicenter, double-blind study to compare the efficacy and safety of once daily atorvastatin and aimvastatin in asian people with elevated LDLcholesterol. Result from ASIA study. J Formos Med Assoc 2002; 101:478-87.
14. Ooi EM, Watts GF, Chan DC, et al. Dose-dependent effect of rosuvastatin on VLDL-apolipoprotein C-III kinetics in the metabolic syndrome. Diebetes Care 2008;31:1656-61.
15. Okubo M, Murase T. Hypertriglyceridemia and low HDL cholesterol in Japanese patients with NIDDM. Diabetes 1996;45:123-5.
16. Kuo CK, Lin LY, Yu YH, et al. A family history of diabetes mellitus is associated with poor glycemic control and increased metabolic risks among people with diabetes: data from the National Health and Nutrition Examination Survey 1999-2004. Intern Med 2010; 49:549-55.
17. Dailey GE 3rd, Mohideen P, Fiedorek FT. Lipid effects of glyburide/ metformin tablets in patients with type 2 diabetes mellitus with poor glycemic control and dyslipidemia in an openlabel extension study. Clin Ther 2002;24:1426-38.
18. Genest J, Frohlich J, Steiner G. Effect of fenofibrate-mediated increasing in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitus. Am J Cardiol 2004; 93:848-53.